Our current study adds further support for this hypothesis, with heterozygous BRCA1 and BRCA2 loss-of-function alleles being associated with 2.1 and 1.18 years earlier ANM, respectively. The gene discussed is BRCA2; the disease is nemaline myopathy 5.